| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
49.07(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $5.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
37,487 |
181,676 |
258,494 |
1,542,385 |
| Total Sell Value |
$29,070 |
$127,826 |
$332,564 |
$10,118,767 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
15 |
34 |
58 |
106 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-03-02 |
4 |
S |
$9.01 |
$4,651 |
D/D |
(516) |
382,384 |
|
45% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-02-16 |
4 |
S |
$8.32 |
$127,525 |
D/D |
(15,322) |
382,900 |
|
52% |
|
| Bornstein Jeffrey S |
Director |
– • – |
2022-02-10 |
4 |
B |
$8.87 |
$44,350 |
D/D |
5,000 |
35,197 |
2.39 |
-50% |
|
| Atillasoy Ercem |
See Remarks |
• – – |
2022-01-25 |
4 |
S |
$8.24 |
$38,248 |
D/D |
(4,639) |
100,347 |
|
55% |
|
| Hallal David |
Director |
– • • |
2022-01-24 |
4 |
S |
$8.01 |
$136,889 |
D/D |
(17,100) |
2,213,566 |
|
57% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-01-20 |
4 |
S |
$8.75 |
$40,752 |
D/D |
(4,656) |
398,222 |
|
54% |
|
| Sinha Vikas |
See Remarks |
• • – |
2022-01-20 |
4 |
S |
$8.75 |
$56,454 |
D/D |
(6,450) |
858,957 |
|
54% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2022-01-20 |
4 |
S |
$8.75 |
$13,680 |
D/D |
(1,563) |
63,202 |
|
54% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
23,256 |
51,256 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
23,256 |
217,307 |
|
- |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
315,000 |
521,300 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
48,838 |
907,795 |
|
- |
|
| Atillasoy Ercem |
See Remarks |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
23,256 |
123,603 |
|
- |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
23,256 |
405,640 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,442 |
80,644 |
|
- |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-12-02 |
4 |
S |
$17.06 |
$8,770 |
D/D |
(514) |
402,878 |
|
68% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-11-16 |
4 |
S |
$21.13 |
$321,262 |
D/D |
(15,203) |
403,392 |
|
66% |
|
| Jovan-Embiricos Morana |
Director |
– • – |
2021-11-10 |
4 |
AS |
$24.77 |
$19,812 |
I/I |
(800) |
342,693 |
|
-66% |
|
| Jovan-Embiricos Morana |
Director |
– • – |
2021-11-09 |
4 |
AS |
$24.79 |
$94,567 |
I/I |
(3,815) |
342,813 |
|
-66% |
|
| Jovan-Embiricos Morana |
Director |
– • – |
2021-11-05 |
4 |
AS |
$24.80 |
$207,888 |
I/I |
(8,381) |
343,385 |
|
-69% |
|
| Jovan-Embiricos Morana |
Director |
– • – |
2021-10-27 |
4 |
AS |
$24.78 |
$54,511 |
I/I |
(2,200) |
344,642 |
|
-69% |
|
| Jovan-Embiricos Morana |
Director |
– • – |
2021-10-25 |
4 |
AS |
$24.82 |
$192,813 |
I/I |
(7,769) |
344,972 |
|
-70% |
|
| Jovan-Embiricos Morana |
Director |
– • – |
2021-10-22 |
4 |
AS |
$24.77 |
$141,757 |
I/I |
(5,723) |
346,137 |
|
-70% |
|
| Jovan-Embiricos Morana |
Director |
– • – |
2021-10-21 |
4 |
AS |
$24.75 |
$2,475 |
I/I |
(100) |
346,996 |
|
-70% |
|
| Atillasoy Ercem |
See Remarks |
• – – |
2021-10-21 |
4 |
S |
$24.23 |
$36,690 |
D/D |
(1,514) |
104,986 |
|
70% |
|
288 Records found
|
|
Page 7 of 12 |
|
|
0.03 (3.5%) 
